Daniel Shapira - DNA Biomed Internal Auditor
| DNA Stock | ILS 90.60 4.70 4.93% |
Executive
Mr. Daniel Shapira serves as Internal Auditor at DNA Biomedical Solutions Ltd. since April 27, 2010. Prior to this role, Mr. Shapira worked as an Accountant at his own Private Accountancy firm for 20 years. His work experience also includes an Internal Auditor position in various companies for five years since 2010.
| Tenure | 14 years |
| Phone | 972 3 970 5000 |
| Web | https://www.laser-detect.com |
DNA Biomed Management Efficiency
The company has return on total asset (ROA) of (0.0375) % which means that it has lost $0.0375 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2509) %, meaning that it generated substantial loss on money invested by shareholders. DNA Biomed's management efficiency ratios could be used to measure how well DNA Biomed manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | EXECUTIVE Age | ||
| Lior Segal | Bezeq Israeli Telecommunication | 42 | |
| Shelly Bainhoren | Bezeq Israeli Telecommunication | 34 | |
| Timothy Wright | Teva Pharmaceutical Industries | 58 | |
| Linor Yochelman | Bezeq Israeli Telecommunication | 41 | |
| Israel Dreyfuss | ICL Israel Chemicals | N/A | |
| Shmuel Daniel | ICL Israel Chemicals | 62 | |
| Ehud Helft | Elbit Systems | N/A | |
Management Performance
| Return On Equity | -0.25 | |||
| Return On Asset | -0.0375 |
DNA Biomed Solns Leadership Team
Elected by the shareholders, the DNA Biomed's board of directors comprises two types of representatives: DNA Biomed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DNA. The board's role is to monitor DNA Biomed's management team and ensure that shareholders' interests are well served. DNA Biomed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DNA Biomed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eran Goren, Director | ||
| Yacov Nimkovsky, External Director | ||
| Yeonatan Malca, CEO, Director | ||
| Rachel Shavit, External Director | ||
| Michael Gaft, Chief Scientist | ||
| Tony Klein, Vice President - Finance | ||
| Daniel Spira, Internal Auditor | ||
| Daniel Shapira, Internal Auditor | ||
| Zvika LTC, VP Programs | ||
| Zeev Bronfeld, Chairman of the Board and Director | ||
| Ronen Midbari, External Director |
DNA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DNA Biomed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | |||
| Return On Asset | -0.0375 | |||
| Current Valuation | 59.57 M | |||
| Shares Outstanding | 123.16 M | |||
| Shares Owned By Insiders | 54.87 % | |||
| Price To Earning | 22.59 X | |||
| Price To Book | 0.95 X | |||
| EBITDA | 18.42 M | |||
| Net Income | 18.37 M | |||
| Cash And Equivalents | 492 K |
Pair Trading with DNA Biomed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DNA Biomed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DNA Biomed will appreciate offsetting losses from the drop in the long position's value.Moving together with DNA Stock
| 0.69 | FORTY | Formula | PairCorr |
Moving against DNA Stock
| 0.41 | STRS | Strauss Group | PairCorr |
The ability to find closely correlated positions to DNA Biomed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DNA Biomed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DNA Biomed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DNA Biomed Solns to buy it.
The correlation of DNA Biomed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DNA Biomed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DNA Biomed Solns moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DNA Biomed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DNA Biomed Solns. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. Note that the DNA Biomed Solns information on this page should be used as a complementary analysis to other DNA Biomed's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for DNA Stock analysis
When running DNA Biomed's price analysis, check to measure DNA Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNA Biomed is operating at the current time. Most of DNA Biomed's value examination focuses on studying past and present price action to predict the probability of DNA Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNA Biomed's price. Additionally, you may evaluate how the addition of DNA Biomed to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |